RNA Vaccine for Malaria

Palo Alto (17 mi)

Age: 18 - 65

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: BioNTech SE

Trial Summary

What is the purpose of this trial?This trial tests a new RNA-based vaccine called BNT165b1 in healthy volunteers. The vaccine uses genetic instructions to help the body make a piece of the malaria parasite's protein, teaching the immune system to recognize and fight malaria.

Eligibility Criteria

Healthy adults aged 18-55, with a BMI of 18.5-35 kg/m^2 and weighing at least 45 kg can join this malaria vaccine trial. They must have no history of severe allergies to vaccines, autoimmune diseases, or uncontrolled respiratory conditions. Participants should not be pregnant or planning pregnancy soon, agree to use effective contraception, and avoid traveling to malaria regions during the study.

Treatment Details

The trial is testing BNT165b1, an RNA-based vaccine for malaria prevention. It's given in three doses at different strengths to find the safest and most effective dose level. A placebo group is included for comparison.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: BNT165b1Experimental Treatment1 Intervention

Escalating dose levels

Group II: PlaceboPlacebo Group1 Intervention